Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

NTLA

Intellia Therapeutics Inc

Dec 24 • 04:00PM ET

12.05

Dollar change -0.05
Percentage change -0.41	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP BEAM EDIT BNTX SGMO REPL CLLS FDMT PSTX ADPT

| Held by: ARKK VTI VB ARKG XBI IWM VXF VBK IWN IBB

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-5.45	Insider Own	1.71%	Shs Outstand	101.80M	Perf Week	-8.23%
Market Cap	1.23B	Forward P/E	-	EPS next Y	-5.49	Insider Trans	-0.14%	Shs Float	100.10M	Perf Month	-15.73%
Income	-522.28M	PEG	-	EPS next Q	-1.34	Inst Own	92.38%	Short Float	19.79%	Perf Quarter	-41.77%
Sales	43.09M	P/S	28.48	EPS this Y	1.96%	Inst Trans	7.72%	Short Ratio	7.79	Perf Half Y	-47.40%
Book/sh	9.46	P/B	1.27	EPS next Y	-3.34%	ROA	-43.22%	Short Interest	19.81M	Perf Year	-61.58%
Cash/sh	6.46	P/C	1.86	EPS next 5Y	30.00%	ROE	-52.23%	52W Range	11.79 - 34.87	Perf YTD	-60.48%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-22.30%	ROI	-49.98%	52W High	-65.44%	Beta	1.80
Dividend TTM	-	Quick Ratio	6.73	Sales past 5Y	12.09%	Gross Margin	76.36%	52W Low	2.21%	ATR (14)	0.84
Dividend Ex-Date	-	Current Ratio	6.73	EPS Y/Y TTM	-1.73%	Oper. Margin	-1247.99%	RSI (14)	33.72	Volatility	5.45% 5.75%
Employees	526	Debt/Eq	0.11	Sales Y/Y TTM	-16.77%	Profit Margin	-1212.19%	Recom	1.48	Target Price	59.17
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	2.55%	Payout	-	Rel Volume	0.34	Prev Close	12.10
Sales Surprise	10.00%	EPS Surprise	3.60%	Sales Q/Q	-24.02%	Earnings	Nov 07 BMO	Avg Volume	2.54M	Price	12.05
SMA20	-12.56%	SMA50	-21.65%	SMA200	-43.75%	Trades		Volume	859,604	Change	-0.41%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-23-24	Downgrade	Goldman	Buy → Neutral	$136 → $32
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Apr-13-23	Initiated	Canaccord Genuity	Buy	$66
Mar-21-23	Initiated	Bernstein	Outperform	$54
Mar-14-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$54 → $57
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$67
Jan-24-23	Upgrade	Citigroup	Sell → Neutral	$48 → $39
Jan-19-23	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Oct-11-22	Initiated	Morgan Stanley	Overweight	$84
Sep-21-22	Initiated	JP Morgan	Overweight	$85
Sep-01-22	Initiated	Citigroup	Sell	$50
Jun-17-22	Initiated	BMO Capital Markets	Market Perform	$54
Jun-16-22	Initiated	BofA Securities	Buy	$70
Apr-28-22	Initiated	Credit Suisse	Outperform	$100
Feb-18-22	Initiated	William Blair	Outperform	$144
Feb-07-22	Upgrade	Oppenheimer	Perform → Outperform	$145 → $150
Jan-31-22	Initiated	Cowen	Outperform
Jan-07-22	Initiated	Piper Sandler	Overweight	$171
Oct-05-21	Initiated	Guggenheim	Buy	$170
Sep-24-21	Initiated	Stifel	Buy	$173

Show Previous Ratings

Dec-11-24 11:57AM	Why Intellia Therapeutics (NTLA) Is the Worst ARK Stock to Buy According to Short Sellers (Insider Monkey)
Dec-03-24 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.87%
Nov-25-24 04:16PM	BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug (Investor's Business Daily)
07:30AM	Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy (GlobeNewswire)
Nov-22-24 08:30AM	Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock? (Motley Fool)
07:27AM	Loading…
Nov-19-24 07:27AM	Intellia Therapeutics Announces Promising CRISPR Therapy Results (TipRanks)
06:54AM	ReCode to secure funds for cystic fibrosis gene correction treatments (Pharmaceutical Technology)
06:30AM	Intellia Therapeutics price target lowered to $70 from $80 at Wells Fargo (TipRanks)
Nov-18-24 10:24AM	Intellias gene editing therapy shows early potential in rare heart condition (Clinical Trials Arena)
06:53AM	CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest (BioPharma Dive)
Nov-16-24 10:16AM	Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis (GlobeNewswire)
Nov-11-24 12:59PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
12:45PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
Nov-08-24 12:01PM	Intellia Therapeutics Inc (NTLA) Q3 2024 Earnings Call Highlights: Financial Stability and ... (GuruFocus.com)
Nov-07-24 08:55AM	Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Loading…
07:30AM	Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Nov-06-24 09:45AM	Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day? (Motley Fool)
Nov-05-24 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-04-24 08:00AM	This Beaten-Down Stock Could Soar by 354%, According to Wall Street (Motley Fool)
Oct-31-24 07:30AM	Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024 (GlobeNewswire)
03:59AM	Intellia Therapeutics (NTLA): Promising Gene Editing Stock with CRISPR-Cas9 Therapies (Insider Monkey)
Oct-26-24 05:19PM	Intellia Therapeutics Advances with Promising Phase 2 Results (TipRanks)
Oct-25-24 11:02AM	Intellia reports positive data from Phase II study of NTLA-2002 for HAE (Clinical Trials Arena)
08:16AM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
Oct-24-24 07:22PM	Why Intellia Therapeutics Stock Plummeted by 20% Today (Motley Fool) -20.51%
12:17PM	Intellia's Ntla-2002 Shows Promising Results, but Stock Drops Following Phase 2 Data Release (GuruFocus.com)
11:26AM	Intellia Therapeutics stock plunges after phase 2 results from NTLA-2002 study (Investing.com)
08:01AM	Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE) (GlobeNewswire)
07:17AM	Intellia data spark debate about CRISPR drugs potential (BioPharma Dive)
Oct-17-24 10:01AM	Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
06:30AM	Loading…
06:30AM	This Beaten-Down Growth Stock Could Skyrocket 234%, According to Wall Street (Motley Fool)
Oct-16-24 03:51PM	Is Intellia Therapeutics, Inc. (NTLA) the Most Promising Biotech Stock According to Hedge Funds? (Insider Monkey) +5.43%
03:51PM	Intellia Therapeutics, Inc. (NTLA) the Most Promising Biotech Stock According to Hedge Funds? (Insider Monkey)
Oct-10-24 07:30AM	Intellia Therapeutics Announces New Date for Upcoming Investor Webcast (GlobeNewswire)
Oct-09-24 05:32PM	Intellia Therapeutics Inc (NTLA) Q2 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
06:35AM	2 Cathie Wood Stocks That Could Soar 32% and 282%, According to Wall Street (Motley Fool)
Oct-08-24 10:15AM	Intellia Therapeutics begins Phase III trial of hereditary angioedema gene therapy (Clinical Trials Arena)
Oct-07-24 07:30AM	Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE) (GlobeNewswire)
07:15AM	Intellia starts late-stage test of CRISPR therapy for rare swelling disease (BioPharma Dive)
Oct-03-24 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-01-24 07:30AM	Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions (GlobeNewswire) -6.57%
Sep-29-24 05:44AM	2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk (Motley Fool)
Sep-12-24 01:01PM	The Brawl Taking Shape Over Pfizers Multibillion-Dollar Heart Monopoly (The Wall Street Journal)
07:30AM	Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting (GlobeNewswire)
Sep-03-24 04:30PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-14-24 10:29AM	Intellia Therapeutics, Inc. (NTLA): Pioneering Gene Editing Solutions for Health Advancements (Insider Monkey)
Aug-09-24 11:32AM	Intellia's (NTLA) Q2 Earnings & Revenues Fall Shy of Estimates (Zacks)
10:19AM	3 Gene Editing Stocks with Potential to Transform Medicine (InvestorPlace)
Aug-08-24 07:01PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) +5.02%
12:23PM	Merck TIGIT drug fails another trial; Intellia therapy succeeds in HAE study (BioPharma Dive)
08:55AM	Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Aug-06-24 12:48PM	The 3 Best Cathie Wood Stocks to Buy in August 2024 (InvestorPlace)
Aug-01-24 11:15AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates (GlobeNewswire)
Jul-31-24 07:33AM	Vertexs pain drug gets speedy FDA review; Keytruda hits a sales milestone (BioPharma Dive)
Jul-30-24 07:30AM	Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency (GlobeNewswire)
Jul-26-24 09:58AM	Intellia (NTLA) to Report Q2 Earnings: What's in the Cards? (Zacks)
Jul-24-24 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-23-24 02:57PM	7 Biotech Stocks to Keep on Your Clinical Radar (InvestorPlace)
Jul-17-24 01:30PM	3 Gene Editing Stocks That Could Grow Your Wealth (InvestorPlace)
11:30AM	3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition (InvestorPlace)
Jul-11-24 12:00PM	All You Need to Know About Intellia Therapeutics (NTLA) Rating Upgrade to Strong Buy (Zacks) +6.39%
Jul-09-24 07:59AM	3 Profitable CRISPR Stocks Earning Analysts' Praise (InvestorPlace)
07:00AM	The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024 (InvestorPlace)
05:56AM	The Bull Case for Intellia Therapeutics Stock Just Got Even Stronger (Motley Fool)
Jul-08-24 09:00AM	The 3 Best Gene Editing Stocks to Buy in July 2024 (InvestorPlace)
06:00AM	3 Pharma Stocks Already Ushering in the Next Biotech Boom (InvestorPlace)
Jul-05-24 02:14PM	The 3 Best Biotech Stocks to Buy in July 2024 (InvestorPlace)
Jul-02-24 08:30AM	3 Stocks Cathie Wood Just Bought to Get Back on Track in the Second Half of 2024 (Motley Fool)
Jun-28-24 10:28AM	Treasure Hunt: 3 Biotech Stocks Wall Street Hasn't Discovered Yet (InvestorPlace)
Jun-27-24 10:02PM	You've Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever. (InvestorPlace)
10:38AM	Intellia (NTLA) Shares Fall as CFO Glenn Goddard Steps Down (Zacks)
Jun-26-24 09:33PM	Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich (InvestorPlace)
07:30AM	Intellia Therapeutics Announces CFO Transition (GlobeNewswire)
05:22AM	First-of-its-kind Intellia data suggest CRISPR drug could be given more than once (BioPharma Dive)
Jun-25-24 03:30PM	Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform (GlobeNewswire)
08:00AM	3 Gene Editing Stocks That Could Make Your Grandchildren Rich (InvestorPlace)
Jun-21-24 06:30AM	Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for June 2024 (InvestorPlace)
Jun-17-24 07:30AM	Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024 (GlobeNewswire)
Jun-14-24 11:49AM	Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry (Zacks)
07:30AM	Intellia Therapeutics Names Brian Goff to its Board of Directors (GlobeNewswire)
Jun-09-24 06:20AM	Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought (Motley Fool)
Jun-08-24 07:25AM	These 2 Words Are Why Intellia Therapeutics Could Be a Smart Buy Right Now (Motley Fool)
Jun-07-24 11:25AM	Cathie Wood Invests In 2 Biotechnology Stocks Are They Worth Buying? (Benzinga)
Jun-06-24 11:05AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Jun-05-24 01:35PM	The 3 Best Biotech Stocks to Buy in June 2024 (InvestorPlace)
Jun-04-24 11:21AM	Intellia (NTLA) Up on Upbeat Long-Term Angioedema Study Data (Zacks)
06:45AM	Cathie Wood Is Buying the Dip on These 2 Biotech Stocks. Should You? (Motley Fool)
Jun-03-24 04:31PM	Is Intellia Therapeutics, Inc. (NASDAQ:NTLA) the Most Promising Gene Therapy Stock to Buy Now? (Insider Monkey) +10.01%
04:17PM	9 Best Gene Therapy Stocks to Buy Now (Insider Monkey)
Jun-02-24 08:00AM	Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE) (GlobeNewswire)
May-25-24 08:30AM	ARK Invest's Cathie Wood Snags These 3 Bargains Are They Right for Your Portfolio? (Benzinga)
May-22-24 11:15AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
May-14-24 12:46PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
09:30AM	Intellia Therapeutics, Inc. (NTLA) Just Overtook the 50-Day Moving Average (Zacks)
May-13-24 02:18PM	15 Best ARK Stocks To Buy Now (Insider Monkey)
May-10-24 03:35PM	Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2024 Earnings Call Transcript (Insider Monkey)
01:16PM	Intellia Therapeutics Q1 2024 Earnings: Aligns with Analyst Projections Amidst Strategic Advances (GuruFocus.com)
11:45AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dube Michael P	VP, Chief Accounting Officer	Oct 02 '24	Sale	19.01	2,012	38,248	47,012	Oct 04 05:29 PM
Clark Eliana	EVP, Chief Technical Officer	Jul 01 '24	Sale	22.93	405	9,287	71,470	Jul 03 01:15 PM
Verwiel Frank	Director	Jun 17 '24	Sale	25.00	1,505	37,625	17,948	Jun 20 05:00 PM
BASTA JAMES	EVP, General Counsel	Mar 04 '24	Sale	32.99	2,297	75,778	81,571	Mar 05 04:10 PM
Clark Eliana	EVP, Chief Technical Officer	Mar 04 '24	Sale	32.99	605	19,959	71,470	Mar 05 04:10 PM
Sepp-Lorenzino Laura	EVP, Chief Scientific Officer	Jan 08 '24	Sale	28.87	2,275	65,682	43,927	Jan 10 04:15 PM
LEONARD JOHN M	President and CEO	Jan 03 '24	Sale	29.46	19,223	566,310	846,486	Jan 05 04:51 PM
Lebwohl David	EVP, Chief Medical Officer	Jan 03 '24	Sale	29.46	5,843	172,135	54,372	Jan 05 04:50 PM
Sepp-Lorenzino Laura	EVP, Chief Scientific Officer	Jan 03 '24	Sale	29.46	5,532	162,973	46,202	Jan 05 04:50 PM
Goddard Glenn	EVP, Chief Financial Officer	Jan 03 '24	Sale	29.46	5,365	158,053	40,585	Jan 05 04:49 PM
Hicks Derek	EVP, Chief Business Officer	Jan 03 '24	Sale	29.46	3,877	114,216	36,987	Jan 05 04:46 PM
BASTA JAMES	EVP, General Counsel	Jan 03 '24	Sale	29.46	3,805	112,095	51,474	Jan 05 04:45 PM
Clark Eliana	EVP, Chief Technical Officer	Jan 03 '24	Sale	29.50	4,608	135,954	40,845	Jan 05 04:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NTLA

Intellia Therapeutics Inc

Upgrade your FINVIZ experience